{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:15Z","timestamp":1792273515309,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["38148"],"award-info":[{"award-number":["38148"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10735-026-10944-7","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:08:54Z","timestamp":1787018934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunohistochemical expression of JAK2, STAT3, POLH, UBE2T, and REV7 in serous ovarian carcinoma: clinicopathological associations and co-expression patterns"],"prefix":"10.1007","volume":"57","author":[{"given":"Mayada Saad","family":"Farrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokia","family":"Masoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2721-5591","authenticated-orcid":false,"given":"Mohamed S.","family":"Hemeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Emarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled El","family":"Naghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine Saad","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf Taha","family":"Ibrahiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Ehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed Elsayed","family":"Elrefaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"10944_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fonc.2014.00075","volume":"4","author":"K Abubaker","year":"2014","unstructured":"Abubaker K, Luwor RB, Zhu H et al (2014) Targeted disruption of the JAK2\/STAT3 pathway, in combination with systemic administration of paclitaxel, inhibits the priming of ovarian cancer stem cells, leading to a reduced tumor burden. Front Oncol 4:75","journal-title":"Front Oncol"},{"key":"10944_CR2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/cancers15041276","volume":"15","author":"GA Atallah","year":"2023","unstructured":"Atallah GA, Mohamed SY, Elhady MT et al (2023) Predicting prognosis and platinum resistance in ovarian cancer: the role of immunohistochemistry biomarkers. Cancers (Basel) 15:1276","journal-title":"Cancers (Basel)"},{"key":"10944_CR3","doi-asserted-by":"publisher","first-page":"15731","DOI":"10.3390\/ijms242015077","volume":"24","author":"E Azzalini","year":"2023","unstructured":"Azzalini E, Cancila V, De Santis MC et al (2023) Overview of tumor heterogeneity in high-grade serous ovarian cancers. Int J Mol Sci 24:15731","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10944_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"3","key":"10944_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2022) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10944_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13048-022-01034-9","volume":"15","author":"P Cui","year":"2022","unstructured":"Cui P, Li H, Wang C, Liu Y, Zhang MJ, Yin Y et al (2022) UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. J Ovarian Res 15(1):103","journal-title":"J Ovarian Res"},{"issue":"1","key":"10944_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13048-021-00918-6","volume":"14","author":"S Gao","year":"2021","unstructured":"Gao S, Zhang W, Yan N, Li M, Mu X, Yin H et al (2021) The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 14(1):164","journal-title":"J Ovarian Res"},{"issue":"5","key":"10944_CR8","first-page":"8421","volume":"20","author":"B Haynes","year":"2015","unstructured":"Haynes B, Saadat N, Myung B, Shekhar MPV (2015) Crosstalk between translesion synthesis, Fanconi anemia, and homologous recombination pathways in interstrand crosslink repair and cancer. Molecules 20(5):8421\u20138438","journal-title":"Molecules"},{"issue":"11","key":"10944_CR9","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1158\/1055-9965.EPI-08-0645","volume":"17","author":"JL Hecht","year":"2008","unstructured":"Hecht JL, Kotsopoulos J, Gates MA et al (2008) Validation of tissue microarray technology in ovarian cancer: results from the Nurses\u2019 Health Study. Cancer Epidemiol Biomark Prev 17(11):3043\u20133050","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"10944_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1080\/15384101.2022.2031426","volume":"21","author":"W Huang","year":"2022","unstructured":"Huang W, Zhang Y, Chen Y et al (2022) UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT\/mTOR-dependent manner in ovarian cancer. Cell Cycle 21(8):780\u2013791","journal-title":"Cell Cycle"},{"issue":"12","key":"10944_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M K\u00f6bel","year":"2008","unstructured":"K\u00f6bel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C et al (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):e232. https:\/\/doi.org\/10.1371\/journal.pmed.0050232","journal-title":"PLoS Med"},{"issue":"11","key":"10944_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD (2015) Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5(11):1137\u20131154","journal-title":"Cancer Discov"},{"key":"10944_CR13","doi-asserted-by":"crossref","unstructured":"Kurman RJ, Shih IeM (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 24 Suppl 10:x16\u2013x21","DOI":"10.1093\/annonc\/mdt463"},{"key":"10944_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M et al (2017) High-grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1093","journal-title":"Nat Commun"},{"issue":"1","key":"10944_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes12010008","volume":"12","author":"C L\u00f3pez-Portugu\u00e9s","year":"2024","unstructured":"L\u00f3pez-Portugu\u00e9s C, Montes-Bay\u00f3n M, D\u00edez P (2024) Biomarkers in ovarian cancer: towards personalized medicine. Proteomes 12(1):8. https:\/\/doi.org\/10.3390\/proteomes12010008","journal-title":"Proteomes"},{"issue":"6","key":"10944_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2144\/btn-2020-0095","volume":"69","author":"T MacNeil","year":"2020","unstructured":"MacNeil T, Vathiotis IA, Martinez-Morilla S et al (2020) Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry. Biotechniques 69(6):460\u2013468. https:\/\/doi.org\/10.2144\/btn-2020-0095","journal-title":"Biotechniques"},{"key":"10944_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1516165","volume":"14","author":"LR Maggs","year":"2025","unstructured":"Maggs LR, McVey M (2025) REV7: a small but mighty regulator of genome maintenance and cancer development. Front Oncol 14:1516165. https:\/\/doi.org\/10.3389\/fonc.2024.1516165","journal-title":"Front Oncol"},{"issue":"1","key":"10944_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00911-y","volume":"9","author":"SS Manda","year":"2025","unstructured":"Manda SS et al (2025) Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome. NPJ Precis Oncol 9(1):172. https:\/\/doi.org\/10.1038\/s41698-025-00911-y","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"10944_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387\u2013391. https:\/\/doi.org\/10.1038\/sj.bjc.6602678","journal-title":"Br J Cancer"},{"issue":"5","key":"10944_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/cas.12390","volume":"105","author":"K Niimi","year":"2014","unstructured":"Niimi K, Murakumo Y, Watanabe N et al (2014) Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells. Cancer Sci 105(5):545\u2013552","journal-title":"Cancer Sci"},{"key":"10944_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32861-5","volume":"13","author":"I Paniagua","year":"2022","unstructured":"Paniagua I et al (2022) MAD2L2 promotes replication fork protection and recovery in a shieldin-independent and REV3L-dependent manner. Nat Commun 13:5167. https:\/\/doi.org\/10.1038\/s41467-022-32861-5","journal-title":"Nat Commun"},{"issue":"1","key":"10944_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"10944_CR23","doi-asserted-by":"publisher","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","volume":"73","author":"CRR Rocha","year":"2018","unstructured":"Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM (2018) DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 73(Suppl 1):e478s","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"10944_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/onc.2016.197","volume":"36","author":"U Saini","year":"2017","unstructured":"Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K et al (2017) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36(2):168\u2013181","journal-title":"Oncogene"},{"issue":"8","key":"10944_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/jnci\/djy088","volume":"110","author":"W Sauerbrei","year":"2018","unstructured":"Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803\u2013811. https:\/\/doi.org\/10.1093\/jnci\/djy088","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10944_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IeM. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484\u2013486. https:\/\/doi.org\/10.1093\/jnci\/95.6.484","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10944_CR27","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1073\/pnas.1421365112","volume":"112","author":"AK Srivastava","year":"2015","unstructured":"Srivastava AK, Han C, Zhao R, Cui T, Dai Y, Mao C et al (2015) Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci USA 112(14):4411\u20134416","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10944_CR28","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.3390\/ijms24087027","volume":"24","author":"D Standing","year":"2023","unstructured":"Standing D, Ottevanger PB, de Bock GH et al (2023) The role of STATs in ovarian cancer: exploring their potential for therapy. Int J Mol Sci 24(8):7027","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10944_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nmeth.3995","volume":"13","author":"M Uhlen","year":"2016","unstructured":"Uhlen M, Bandrowski A, Carr S et al (2016) A proposal for validation of antibodies. Nat Methods 13(10):823\u2013827. https:\/\/doi.org\/10.1038\/nmeth.3995","journal-title":"Nat Methods"},{"issue":"1","key":"10944_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association (2025) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA 333(1):71\u201374. https:\/\/doi.org\/10.1001\/jama.2024.21972","journal-title":"JAMA"},{"issue":"2","key":"10944_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.19723\/j.issn.1671-167X.2023.02.010","volume":"55","author":"J Yang","year":"2023","unstructured":"Yang J, Du J, Wang YX, Liu CR (2023) Activation of JAK\/STAT in ovarian high-grade serous cancers and its prognostic significance. Beijing Da Xue Xue Bao Yi Xue Ban 55(2):270\u2013275. https:\/\/doi.org\/10.19723\/j.issn.1671-167X.2023.02.010","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"4","key":"10944_CR32","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.3892\/ol.2018.8028","volume":"15","author":"T Yoshikawa","year":"2018","unstructured":"Yoshikawa T, Miyamoto M, Aoyama T et al (2018) JAK2\/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett 15(4):5772\u20135780. https:\/\/doi.org\/10.3892\/ol.2018.8028","journal-title":"Oncol Lett"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10944-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-10944-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-10944-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:40Z","timestamp":1792271980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-10944-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10944"],"URL":"https:\/\/doi.org\/10.1007\/s10735-026-10944-7","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Scientific Research Ethics Committee of the Faculty of Medicine, Mansoura University, Egypt (Proposal Code: R.25.11.3460). The study was conducted in accordance with the Declaration of Helsinki. Given the retrospective nature of the study and the use of archived formalin-fixed paraffin-embedded tissue specimens and existing medical records, the approving committee waived the requirement for informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"274"}}